George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 107.50
Bid: 105.00
Ask: 110.00
Change: 0.00 (0.00%)
Spread: 5.00 (4.762%)
Open: 107.50
High: 107.50
Low: 107.50
Prev. Close: 107.50
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European Marketing Authorisation Opinion

22 May 2020 07:00

RNS Number : 6812N
Eco Animal Health Group PLC
22 May 2020
 

 

 22 May 2020

ECO Animal Health Group plc

(the "Group")

(AIM: EAH)

 

EUROPEAN POSITIVE OPINION FOR AIVLOSIN® IN PIGS

ECO Animal Health Group plc (the "Group") is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens.

Aivlosin®, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

The European Commission is expected to issue a marketing authorisation within two months of the publication of a positive opinion.

Marc Loomes, CEO, commented: "Aivlosin® offers a safe and highly effective medication for Mycoplasma infections. This positive opinion is significant, not only in the EU which has fifteen per cent of the world's pigs but for other large international swine markets as this indication is rolled out. Whilst we bring forward our new product development programme, particularly around vaccines, it is important to note that Aivlosin® 's approved usage continues to expand across multiple treatment areas and markets."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts: 

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)

020 8447 8899

IFC Advisory

Graham Herring

Zach Cohen

020 3934 6630

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Alex Bond

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCABMFTMTJTBMM
Date   Source Headline
26th Aug 20221:13 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHolding(s) in Company
22nd Aug 20227:00 amRNSRevised Notice of Results
9th Aug 20227:00 amRNSDirectorate Change
8th Aug 202211:05 amRNSSecond Price Monitoring Extn
8th Aug 202211:00 amRNSPrice Monitoring Extension
8th Aug 20227:00 amRNSNotice of Results and Trading Update
11th Jul 20227:00 amRNSNew Banking Facility
6th Jul 20227:00 amRNSPartnership with Moredun Research Institute
15th Jun 20227:35 amRNSPartnership with Imperial College
12th May 202212:05 pmRNSDirector/PDMR Dealings
29th Apr 202211:47 amRNSBlock Listing Interim Review
1st Apr 20227:00 amRNSDirector/PDMR Dealings
30th Mar 20227:00 amRNSDirector/PDMR Dealings
23rd Mar 20225:53 pmRNSDirector/PDMR Dealing
21st Mar 20227:00 amRNSDirector/PDMR Dealing
15th Mar 20227:00 amRNSPre-close Trading Update
23rd Feb 20227:00 amRNSNew Marketing Authorisations for Aivlosin in China
1st Feb 20221:53 pmRNSHolding(s) in Company
24th Jan 20227:00 amRNSInvestor Presentation
18th Jan 20227:01 amRNSHolding(s) in Company
18th Jan 20227:00 amRNSChief Executive Officer Appointment
13th Jan 20229:29 amRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update, Appointment of Joint Broker & CMD
6th Dec 20218:14 amRNSHolding(s) in Company
1st Dec 20217:00 amRNSBoard Appointment
30th Nov 202112:39 pmRNSDirector Dealings
25th Nov 20217:00 amRNSResults for the six months ended 30 September 2021
23rd Nov 20217:00 amRNSInvestor Presentation covering Interim Results
1st Oct 20218:47 amRNSTotal Voting Rights & Share Capital
27th Sep 202112:06 pmRNSDeferred Share Awards to Executive Directors
17th Sep 20217:00 amRNSResult of AGM
16th Sep 20217:00 amRNSAGM Statement
19th Aug 20217:00 amRNSPublication of Annual Report and Notice of AGM
12th Aug 20218:30 amRNSHolding(s) in Company
28th Jul 20212:40 pmRNSDirectors Dealings
26th Jul 20217:00 amRNSBoard Changes
26th Jul 20217:00 amRNSFinal Results for Year Ended 31 March 2021
28th May 20212:31 pmRNSTotal Voting Rights
12th May 20211:55 pmRNSHolding(s) in Company
30th Apr 20212:00 pmRNSBlock listing Interim Review
30th Apr 20212:00 pmRNSTotal Voting Rights
29th Apr 20217:00 amRNSDirector/PDMR Shareholding
21st Apr 20214:33 pmRNSDirector/PDMR Shareholding
8th Mar 20217:00 amRNSTrading Update
4th Mar 20213:07 pmRNSResult of AGM & GM
25th Feb 202111:15 amRNSClarification of new long term incentive plan
18th Feb 20211:59 pmRNSHolding(s) in Company
4th Feb 20217:30 amRNSRestoration - Eco Animal Health Group plc
4th Feb 20217:10 amRNSAnnual & Interim Reports Publication & AGM Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.